Ensysce Biosciences Past Earnings Performance
Past criteria checks 0/6
Ensysce Biosciences's earnings have been declining at an average annual rate of -6.6%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 0.8% per year.
Key information
-6.6%
Earnings growth rate
20.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -0.8% |
| Return on equity | -120.5% |
| Net Margin | -179.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Ensysce Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 4 | -8 | 5 | -2 |
| 30 Jun 24 | 1 | -11 | 5 | 0 |
| 31 Mar 24 | 2 | -12 | 5 | 0 |
| 31 Dec 23 | 2 | -11 | 5 | 0 |
| 30 Sep 23 | 3 | -13 | 5 | 0 |
| 30 Jun 23 | 3 | -20 | 5 | 0 |
| 31 Mar 23 | 3 | -26 | 6 | 0 |
| 31 Dec 22 | 3 | -25 | 7 | 0 |
| 30 Sep 22 | 3 | -30 | 7 | 0 |
| 30 Jun 22 | 4 | -38 | 22 | 0 |
| 31 Mar 22 | 4 | -31 | 20 | 0 |
| 31 Dec 21 | 4 | -30 | 19 | 0 |
| 30 Sep 21 | 2 | -19 | 18 | 0 |
| 30 Jun 21 | 2 | 0 | 1 | 0 |
| 31 Mar 21 | 3 | 0 | 1 | 0 |
| 31 Dec 20 | 4 | 0 | 1 | 0 |
| 31 Dec 19 | 2 | -10 | 7 | 0 |
Quality Earnings: ENSC is currently unprofitable.
Growing Profit Margin: ENSC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ENSC is unprofitable, and losses have increased over the past 5 years at a rate of 6.6% per year.
Accelerating Growth: Unable to compare ENSC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ENSC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ENSC has a negative Return on Equity (-120.48%), as it is currently unprofitable.